1. Home
  2. VITL vs TBPH Comparison

VITL vs TBPH Comparison

Compare VITL & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$20.04

Market Cap

944.3M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.56

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
TBPH
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.3M
1.0B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
VITL
TBPH
Price
$20.04
$13.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$42.56
$20.20
AVG Volume (30 Days)
2.1M
675.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
22.03
N/A
EPS
1.44
0.88
Revenue
$759,444,000.00
$15,386,000.00
Revenue This Year
$26.07
$70.90
Revenue Next Year
$20.95
N/A
P/E Ratio
$13.90
$15.55
Revenue Growth
25.26
N/A
52 Week Low
$19.75
$7.90
52 Week High
$53.13
$21.03

Technical Indicators

Market Signals
Indicator
VITL
TBPH
Relative Strength Index (RSI) 23.17 22.48
Support Level N/A $13.58
Resistance Level $31.02 $14.76
Average True Range (ATR) 1.24 0.93
MACD -0.58 -0.66
Stochastic Oscillator 3.04 7.31

Price Performance

Historical Comparison
VITL
TBPH

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: